ESTRO 2020

Vienna, Austria

It is my privilege and great pleasure to invite you to ESTRO 2020 that will take place 3-7 April 2020 in Vienna, Austria. 

We are pleased that this year the World Congress of Brachytherapy will take place adjacent to ESTRO 2020 from 2-4 April 2020 in the same venue as ESTRO 2020.

ESTRO is a multi-professional society focusing on radiation oncology as a core component of high- quality, multidisciplinary cancer treatment, in partnership with other oncology societies.

[see more]

Scientific programme committee

  • Chair of the congress: Umberto Ricardi (IT)

Scientific Advisory Group (SAG) chairs:

  • Ben Slotman (NL), Chair of interdisciplinary track
  • Heidi Lyng (NO), Chair, SAG Radiobiology
  • Eduard Gershkevitsh (EE), Chair, SAG Radiation Physics
  • Esther Troost (DE), Chair, SAG Clinical Radiotherapy
  • Aileen Duffton (UK), Chair, Radiation Therapy
  • Jolien Heukelom (NL), Chair, Young track
  • Steven Petit (NL) ,Chair, Young track
  • Bradley Pieters (NL), Chair, World Congress of Brachytherapy
  • Members: Ludwig Dubois (NL), Pierfrancesco Franco (IT), Yolande Lievens (BE), Anthony Chalmers (UK), Marco Schwarz (IT), Karin Haustermans (BE), Filipe Moura (PT), Christian Kirisits (AT), Michael Baumann (DE), Jens Overgaard (DK), Pierre Blanchard (FR), Ludvig Muren (DK), Michelle Leech (IE)

Read the full list of SPC members

Conference secretariat

ESTRO Office 
Rue Martin V, 40 
1200 Brussels 

General queries: contact us

Abstract queries: contact us

  • Abstract submission: 23 October 2019

  • Early registration: 14 January 2020

  • Late abstract submission: 15 January 2020

  • Late registration: 3 March 2020


Reed Messe Vienna GmbH
Congress Center
Messeplatz 1
A-1021 Vienna, Austria
ESTRO 2020 main entrance: Hall D
Metro stop: Krieau



Mondial Congress & Events has been appointed the official hotel provider for the congress.


Make your reservation via the online booking website:

Group hotel bookings for 10 or more delegates are made via a group booking form.

Please contact Ellen from Mondial Congress & Events, to arrange details and obtain the forms.

Ellen Valckenaere

Mondial GmbH & Co KG

Mondial Congress & Events
Operngasse 20B, 1040 Vienna, Austria
Tel: +43 (0)1 58804 143


DEADLINE: 23 October 2019 (23.59 HRS CET)


Abstracts must be submitted on-line on the ESTRO website at:

We highly recommend completing your submission early - otherwise authors may experience technical delay due to server overload.

For questions regarding the on-line submission process, please e-mail


With the submission of an abstract for ESTRO 2020, the corresponding (presenting) author:

• Accepts responsibility for the accuracy of the abstract and ascertains that all authors are aware of the content before submission

• Accepts to be the contact person for all correspondence related to the abstract and to inform the co-authors about its status

• Accepts to identify any financial interest in products or processes described in the abstract. This includes stock ownership, membership on any advisory boards, commercially sponsored research or any other substantial relationships

• Certifies that the information to be reported is for exclusive presentation in the session to which the abstract will be assigned if accepted and that the information will not be presented as such at any commercially sponsored satellite symposia during the conference.

Further notes:

• Please log in to the abstract submission site with the presenting author login details

• Abstracts must be submitted and presented at the conference in English. The Scientific Committee reserves the right to reject an abstract written in poor English

• Abstracts will be anonymised before review to ensure fairness and eliminate possible bias. Therefore, it is strictly forbidden to include the authors’ names or institutions in the body of the abstracts.


• Track: choose a track keeping in mind that:

• Abstracts submitted under the Clinical track are reviewed by clinicians and considered for the clinical track of ESTRO 2020

• Abstracts submitted under the Physics track are reviewed by physicists and considered for the physics track of ESTRO 2020

• Abstracts submitted under the Radiobiology track are reviewed by radiobiologists and considered for the radiobiology track of ESTRO 2020

• Abstracts submitted under the RTT track are reviewed by Radiation TherapisTs (RTTs) and considered for the RTT track of ESTRO 2020 only.

Brachytherapy abstracts should be submitted for the World Congress of Brachytherapy.

It is extremely important that you submit your abstract under the correct track. Submitting under the wrong track will result in your abstract being sent to the wrong experts for review and being scored low as a consequence.

Further advice for submitters:

• Delineation abstracts: if the focus of the abstract is on imaging techniques, then the abstract should be submitted under the physics topics; if the focus of the abstract is on correctness of TV, OAR, then the abstract should be submitted under the clinical topics or under the RTT topics

• Clinical outcome: If there is no clinical outcome (at least toxicity reporting) the abstract should be submitted under the physics topics (or brachytherapy topics).

• Topic category: choose the topic category that refers to the main subject of the abstract. The Scientific Committee reserves the right to re-categorise the abstract.

• Keywords: authors are required to select a keyword from a pre-defined menu. The list of keywords corresponding to each topic category indicated in the table can be a useful guide to determine the most appropriate topic category under which to submit the abstract. When submitting your abstract only one keyword can be selected from the pre-defined list.

• Presentation preference: authors should indicate the presentation preference (oral, poster or no preference). Please note that the final decision on the presentation format rests with the Scientific Committee.

• Title: abstract titles should be brief and reflect the content of the abstract. The title (maximum 100 characters) is important since it focuses attention (it is the “showcase” for the presentation). Do not use capital letters in the title except for words that are always capitalised and do not use non-standard abbreviations.

• Body of the abstract: abstracts should be structured in such a way as to include (1) Purpose/Objective; (2) Material/methods; (3) Results; (4) Conclusion.

• The on-line abstract submission procedure: the on-line abstract submission system will not accept abstracts that exceed 3,000 characters (body of the abstract, including spaces).

• The use of standard abbreviations is desirable. A special or unusual abbreviation must be placed (in round brackets) after the first appearance of the word for which it stands.

• Table and image: with their submission authors may include maximum two (2) uploads (tables or images) in JPG, PNG or TIFF formats. These uploads are not included in the number of characters. The maximum pixel size of an image is 600(w) x 800 (h) pixel.

• Data table: authors may include one data table using the insert table icon (we advise not to copy-paste a table into the body of the abstract). The characters in a data table are included in the overall number of characters allowed.

• Equations: can be inserted in the text as images.


Abstracts submitted for presentation will be reviewed by an international panel of experts in the field of the subject.

Abstract review criteria are based on clarity, supporting data, scientific rigour, potential significance, interest in the topic chosen and innovation or usefulness.

Work in progress: abstracts on research obviously not yet performed and results not yet obtained will be banned.

Encore abstracts: papers already presented in another meeting will not be considered, unless the previous audience is distinct from the ESTRO 2020 congress audience (e.g. national meetings).

Papers already accepted for publication will not be considered.

Abstracts will be selected for one of the following presentation formats:

Oral presentation: abstracts selected for oral presentation are presented at one of the proffered paper sessions scheduled in the programme.

Poster: abstracts selected as poster will be presented in one of the following three presentation formats:

Poster Highlights: Poster (in printed version) is to be mounted on the designated poster panel in the poster area. The poster is presented/discussed verbally during a Poster Highlights session in the poster area at the poster grouping of your topic. These sessions will be led by two chairpersons. The authors of the selected posters will visit all the posters within each group (topic), along with the session chairs and participants. Each author will present his/her poster verbally in 5 minutes, followed by 3 minutes for discussion.

Authors of the abstracts selected for a Poster Highlights session must print their poster via the ESTRO subsidised poster platform. More information will be provided in due time.

Poster Discussion: Poster (in electronic version only) is presented/discussed verbally during a Poster Discussion session. Poster Discussion sessions will take place during the designated coffee breaks. These sessions will be led by two chairpersons. The author will present his/her poster verbally around a station where the posters are shown in electronic format in 3 minutes, and then there will be 2 minutes for discussion.

Authors of the abstracts selected for a Poster Discussion session must upload an electronic version of their poster via the ESTRO subsidised poster platform. More information will be provided in due time.

Poster: Poster (in electronic version only) will be available for viewing at special stations in the congress venue. These posters in electronic format are not discussed by the authors during specific sessions in the programme. However, authors are free to invite interested participants to one of the e-poster stations to explain the poster content during the congress.

Authors of the abstracts selected as Poster must upload an electronic version of their poster via the ESTRO subsidised poster platform. More information will be provided in due time.

Withdrawal of an abstract: abstracts submitted for ESTRO 2020 can be withdrawn until 10 December 2019 (to withdraw your abstract you should send an email to After this date, withdrawal of abstracts is no longer possible. Abstracts selected for oral / poster presentation should be presented at the meeting. In case the first (presenting) author cannot attend the conference, he / she should assign a replacement and inform the ESTRO office of the replacement as soon as possible.

Notification of outcome of abstract submission will be sent by the second week of January 2020.

The notification email is sent to the email address of the person whose credentials were used to login to the submission page.


• The work and/or update must be novel, ground-breaking, of high significance, evidence-based and with scientific merit

• The work and/or update must be original and not previously have been published or presented at any other scientific meeting

• The abstract must present timely findings which were not available at the time of the deadline (23 October 2019). The late breaking abstract deadline is not intended to be a second deadline for abstract submissions.

• A limited number of late-breaking abstracts will be accepted

• Submissions will be accepted for oral presentation only.

The deadline for late-breaking abstracts is 15 January 2020.


Health Services Research (HSR) and Health Economics in Radiation Oncology (HERO)  

Friday, 3 April 2020 from 08:30-17:00 

Course directors: Y. Lievens (BE) and E. Zubizarreta (AT) 

Course aim  

The general objectives of healthcare are to ascertain quality, availability, accessibility and efficiency of care. In an era of tight healthcare budgets, all these aspects are more than ever relevant.  

Besides the slow transition of clinical evidence into daily practice due to patient and physician factors, the limited availability of resources - often consequence of socio-economic factors - may be limiting access to healthcare, especially to innovative treatments that typically come with a higher cost. Accurately estimating the cost of new radiation treatments remains a challenge but it is required as a first step to determine their cost-effectiveness (i.e. efficiency), hence acceptability, from a societal perspective. To do so, economic evaluations are performed, balancing their additional costs to their expected clinical benefits, compared to standard-of-care. In addition, budget impact analyses define whether the introduction of new interventions in daily practice is affordable, now, and in the future. Value also weighs costs and outcomes, however, puts the patient, and the outcome most favoured by the patient, in the centre of the equation.  

All these aspects are part of a broader health technology assessment program that should endorse the uptake of established and valuable new interventions by the healthcare system, hence support their reimbursement. 

Learning Objectives  

To provide understanding of: 

•       The availability and accessibility of radiotherapy services and resources; 

•      The needs of radiotherapy, both in terms of number of treatments delivered as of resources required to deliver these treatments; 

•       How radiotherapy resource costs are calculated; 

•      How costs relate to reimbursement and how the reimbursement system can drive practice; 

•       Economic evaluations, with a focus on the context of radiotherapy; 

•       Budget impact analysis, with a focus on the context of radiotherapy; 

•       How investment cases can be developed for radiotherapy; 

•       What value-based healthcare means for radiotherapy; 

To facilitate: 

•       Networks between radiation oncology professionals interested in different aspects of health services research 

Who should attend 
Radiation oncologists, medical physicists, RTTs with an interest of how health services research impacts the way we can deliver care to our patients; health economists and health services researchers with an interest in oncology and radiotherapy. 



Artificial intelligence for clinicians

Friday, 3 April 2020 from 08:30-17:00

Course directors: E. Sterpin (BE) and M. Dahele (NL)

Course aim

Artificial intelligence (AI) is predicted to revolutionize many sectors, including healthcare. The aim of this one-day course is to provide a state-of-the-art, critical, overview of (selected) AI-related developments in radiotherapy.

Learning objectives

- Describe the fundamentals of AI-related software (machine learning, neural network, deep learning)
- Evaluate and criticise AI-based automatic clinical workflows, ranging from specific tasks like segmentation, to the adaptive radiotherapy workflow 
- Consider AI and Big data for discovering new paradigms in clinical practice
-  Be able to identify how AI may present opportunities to advance their own research and clinical interests
-  Be aware of the social dimension of AI and automation, including how they might affect jobs

Who should attend?

AI is likely to touch the whole of radiotherapy, from specific tasks like segmentation and treatment planning, to workflows like adaptive radiotherapy, to treatment selection and patient outcomes. Therefore, in addition to physicists, we anticipate that it will also appeal to interested technologists and clinicians



The evolving role of medical physicists in clinical trials

Friday, 3 April 2020 from 08:30-17:00

Course Directors: D. Fuller (US) and M. Aznar (UK)

Course aim

To review the life cycle of radiotherapy clinical trials and to encourage medical physicists to participate actively at all stages of clinical trial design, management and analysis.

Learning objectives

By the end of this course participants should be able to:

  • Discuss and contribute to the different steps in the process of clinical trial design
  • Understand the basic elements of radiotherapy trial QA and be able to construct a basic QA programme for a radiotherapy trial
  • Conduct sample size calculations for simple randomised trial designs
  • Learn where and how to access data from completed clinical trials
  • Understand how physicists can contribute to current clinical trials (ongoing or in development) inside and outside your own institution.
  • Assess the directions of future medical physics research / development related to, e.g. QA and imaging Biomarkers

Who should attend?

This course is designed for medical physicists, but other specialties are welcome. Participants do NOT need to have experience with or work in an institution involved in clinical trials. Participants be given the basics to get started and discuss other ways to be involved, e.g. how to build projects based on publicly available data sources or contribute to national trials groups.



Interaction between the tumor ecosystem (microenvironment) and radiation

Friday, 3 April 2020 from 08:30-17:00

Course Directors: J. Bussink (NL) and U. Gaipl (DE)

Course aim

To become acquainted with how radiation impacts the tumor and its microenvironment and the subsequently responses.

Learning objectives

Participants will obtain knowledge on cellular and molecular processes in tumor cells and cells of the tumor microenvironment that are jolted by radiation, the consecutive direct or indirect modulation of the tumor microenvironment and systemic responses and the final consequences for anti-tumor immunity as well as tissue side reactions.

Who should attend?

Radiobiologists, Clinicians, Physicists, Technicians



Research for RTTs

Friday, 3 April 2020 from 08:30-17:00

Course directors: A. Duffton (UK) and Y. Tsang (UK)

Course aim

The course is directed at RTTs and professionals either interested in developing research expertise, or/and leading research teams. Aspects covered will include study design, through to analysis and dissemination of projects. The course will allow networking with other RTTs research active in research and encourage future collaborations.

This pre-meeting course aims to enable attendants:

  • To learn how to develop and lead an initial clinical research idea into a successful project, with scientific output.
  • To evaluate the current trends of radiotherapy research and discuss potential challenges and bottlenecks for future research opportunities.
  • To adopt a critical approach of how to dissertate research findings (such as manuscript writing and research grant applications).

Learning objectives

By the end of this course participants should be able to:

  • Critically evaluate the quality of radiotherapy research concerning novelty, feasibility, potential impact and clinical relevance.
  • Effectively discuss research ideas/projects with colleagues to maximise scientific value.
  • Discuss current trends and research opportunities in radiotherapy and related technical fields.

Who should attend?

  • RTTs who are early starters in research (including MSc students). Possibly, but not necessarily, they have relevant clinical experience outside research.
  • RTTs who want to develop research skills
  • RTTs who want to be more involved in research.



In conjunction with ESTRO 2020 take a look at the course on Foundations of Leadership in Radiation Oncology held on 2-3 April 2020.

ESTRO welcomes the interest of the press in cancer issues and is happy to provide assistance to journalists attending ESTRO 2020 from 03-07 April 2020, or using the congress website as a resource in their coverage of cancer issues. 

ESTRO Anniversary Initiatives

Download the Final Announcement